Skip to main content

Table 1 Pretabalumab baseline demographics and clinical characteristics a

From: A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

  Tabalumab (60 mg) Tabalumab (60 mg/120 mg)
(N = 60) (N = 121)
Males, n (%) 9 (15) 22 (18)
Age, yr 53 ± 12 52 ± 12
Duration of RA, yr 9 ± 7 10 ± 8
Swollen joint count (28) 10.2 ± 6.5 12.2 ± 6.3
Tender joint count (28) 13.1 ± 8.1 16.1 ± 7.6
Physician's Global Assessment (VAS) 48 ± 21 57 ± 22
Patient's Global Assessment of Disease Activity (VAS) 55 ± 23 63 ± 23
Patient's Global Assessment of Pain (VAS) 55 ± 23 60 ± 23
HAQ-DI 1.5 ± 0.7 1.7 ± 0.6
CRP, mg/dl 2.2 ± 1.9 2.3 ± 2.4
DAS28 5.5 ± 1.3 5.9 ± 1.1
Prior TNF exposure, n (%) 17 (28) 58 (48)
Prior HCQ exposure, n (%) 25 (42) 33 (27)
Prior SSZ exposure, n (%) 14 (24) 36 (30)
Weekly dose of MTX, mg 16 ± 4 16 ± 5
Daily dose of prednisone dose, mg 7 ± 3 7 ± 3
Concomitant prednisone, n (%) 38 (64) 92 (76)
  1. aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire-Disability Index; HCQ, Hydroxychloroquine; MTX, Methotrexate; RA, Rheumatoid arthritis; RCT, Randomized control trial; SSZ, Sulfasalazine; TNF, Tumor necrosis factor; VAS, Visual analogue scale. Data are mean ± SD unless noted otherwise. For patients assigned to receive tabalumab in RCT1 or RCT2, pretabalumab baseline data were collected at week 0 of RCT1 or RCT2. For patients assigned to receive placebo in RCT1 or RCT2, pretabalumab baseline data were collected either before patients received an optional 80-mg tabalumab rescue dose at week 16 in RCT1 or at open-label extension study entry. Numbers in bold denote pretabalumab RA activity levels that were greater for the 60-mg/120-mg tabalumab group compared to the 60-mg tabalumab group.